Aetna Beats

Aetna (AET) reported 3rd Quarter September 2017 earnings of $2.45 per share on revenue of $15.0 billion. The consensus earnings estimate was $2.06 per share on revenue of $15.1 billion. The Earnings Whisper number was $2.11 per share. Revenue fell 5.0% compared to the same quarter a year ago.

The company said it expects 2017 earnings of approximately $9.75 per share. The company's previous guidance was earnings of $9.45 to $9.55 per share and the current consensus earnings estimate is $9.55 per share for the year ending December 31, 2017.

Aetna Inc. is a health care benefit company, which offers traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans.

Aetna Reports Third-Quarter 2017 Results

Aetna (AET) announced third-quarter 2017 net income(1) of
$838 million, or $2.52 per share. Adjusted earnings(2) for
third-quarter 2017 were $814 million, or $2.45 per share. Aetnas strong
third-quarter performance resulted in net income of $1.7 billion and
adjusted earnings of $2.9 billion for the nine months ended
September 30, 2017.

"Our third-quarter results are a continuation of our momentum from the
first half of the year," said Mark T. Bertolini, Aetna chairman and CEO.
"Our tireless focus on service and quality are evident in the recently
released 2018 Medicare Star Ratings. For the third year in a row Aetna
has the leading position among publicly-traded companies with the
highest percentage of members in plans rated four stars or higher."

"The strength of our core business fundamentals in the third-quarter was
driven by disciplined pricing, moderate medical cost trend and focused
execution," said Shawn M. Guertin, Aetna executive vice president and
CFO. "We are once again increasing our full year 2017 earnings
projections to reflect the continued strength of our operating results
year to date."

(In millions, except per share data)

Third-Quarter 2017

Full-Year 2017

Revenue

Earnings

EPS

Projected EPS(4)

GAAP

$ 14,994

$ 838

$ 2.52

$5.95

Non-GAAP (Adjusted)

$ 14,948

$ 814

$ 2.45

$9.75

Medical Membership totaled 22.2 million at September 30, 2017

Aetna presents both GAAP and non-GAAP financial measures in this press
release to provide investors with additional information. Refer to
footnotes (1) through (6) for definitions of
non-GAAP financial measures and pages 9 through 11 for reconciliations
of the most directly comparable GAAP financial measures to non-GAAP
financial measures.

Third-Quarter Financial Results at a Glance

Third-Quarter

(Millions, except per common share data)

2017

2016

Change

Total revenue

$ 14,994

$ 15,781

(5 )%

Adjusted revenue(3)

14,948

15,738

(5 )%

Net income(1)

838

604

39 %

Adjusted earnings(2)

814

734

11 %

Per share results:

Net income(1)

$

2.52

$

1.70

48 %

Adjusted earnings(2)

2.45

2.07

18 %

Weighted average common shares - diluted

332.0

354.3

Total Company Results

•
Net income(1) was $838 million for
third-quarter 2017 compared with $604 million for third-quarter 2016.
The increase in net income during third-quarter 2017 was primarily due
to the increase in adjusted earnings described below and lower
transaction and integration-related costs in 2017 compared to 2016.

•
Adjusted earnings(2) were $814 million for
third-quarter 2017 compared with $734 million for third-quarter 2016.
The increase in adjusted earnings during third-quarter 2017 was
primarily due to continued strong performance in Aetnas Health Care
segment.

•
Total revenueand adjusted revenue(3)
were $15.0 billion and $14.9 billion, respectively, for
third-quarter 2017 and were $15.8 billion and $15.7 billion,
respectively, for third-quarter 2016. The decrease in total revenue
and adjusted revenue during third-quarter 2017 was primarily due to
lower premiums in Aetnas Health Care segment, including lower
membership in Aetnas ACA compliant individual and small group
products, and the temporary suspension of the health insurer fee
("HIF") in 2017.

•
Total company expense ratio was 17.4 percent and 17.9 percent
for the third quarters of 2017 and 2016, respectively. The adjusted
expense ratio(5) was 17.5 percent and 17.6 percent for the
third quarters of 2017 and 2016, respectively. The improvement in both
ratios during 2017 was primarily due to the temporary suspension of
the HIF in 2017 and the continued execution of Aetnas expense
management initiatives, largely offset by targeted investment spending
on Aetnas growth initiatives. The total company expense ratio also
improved due to lower transaction and integration-related costs in
third-quarter 2017 compared to 2016.

•
After-tax net income margin was 5.6 percent and 3.8 percent for
the third quarters of 2017 and 2016, respectively. The adjusted
pre-tax margin(6) was 9.2 percent and 8.5 percent for the
third quarters of 2017 and 2016, respectively. The improvement in both
third-quarter 2017 ratios was primarily due to continued strong
performance in Aetnas Health Care segment. The improvement in the
adjusted pre-tax margin was partially offset by the negative impact of
the temporary suspension of the HIF in 2017.

•
Total debt to consolidated capitalization ratio(7) was
39.5 percent at September 30, 2017 compared with 53.6 percent at
December 31, 2016. The total debt to consolidated capitalization ratio
at September 30, 2017 reflects (i) Aetnas decision to pre-fund debt
maturities of approximately $1.0 billion coming due in the fourth
quarter of 2017 with the issuance of $1.0 billion aggregate principal
amount of senior notes during the third quarter of 2017 and (ii) the
repayment of approximately $11.6 billion aggregate principal amount of
Aetnas senior notes during the first half of 2017.

•
Effective tax rate was 33.4 percent for third-quarter 2017
compared with 44.4 percent for third-quarter 2016. The decrease in
Aetnas effective tax rate for third-quarter 2017 was primarily due to
the temporary suspension of the non-deductible HIF in 2017 and
anticipated incremental tax benefits related to certain costs
associated with the Humana transaction incurred in 2017.

Health Care Segment Results

Health Care, which provides a full range of insured and self-insured
medical, pharmacy, dental and behavioral health products and services,
reported:

•
Income before income taxes(1) and pre-tax adjusted earnings(2)
remained relatively consistent at approximately $1.3 billion for the
third-quarters of 2017 and 2016. The third quarter of 2017 reflects
continued strong performance across Aetnas core Health Care
businesses and reduced losses in Aetnas individual Commercial
products, which offset the negative impact of the temporary suspension
of the HIF in 2017.

•
Total revenue was $14.3 billion for third-quarter 2017 and $15.1
billion for third-quarter 2016. Adjusted revenue(3) was
$14.2 billion for third-quarter 2017 and $15.1 billion for
third-quarter 2016. The decrease in total revenue and adjusted revenue
was primarily due to lower membership in Aetnas ACA compliant
individual and small group products, lower membership in Aetnas
Medicaid products and the temporary suspension of the HIF in 2017. The
decrease was partially offset by higher premium yields in Aetnas
Commercial and Government businesses and membership growth in Aetnas
Medicare products.

•
Medical membership at September 30, 2017 increased slightly compared
with June 30, 2017. The increase primarily reflects increases in
Aetnas International Commercial Insured and Commercial ASC products,
partially offset by declines in Aetnas Medicaid and ACA compliant
individual and small group products.

•
Medical benefit ratios ("MBRs") for the three and nine months ended
September 30, 2017 and 2016 were as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

2017

2016

Change

2017

2016

Change

Commercial

81.4

%

83.8

%

(2.4 )

pts.

79.7

%

81.7

%

(2.0 )

pts.

Government

82.4

%

80.1

%

2.3

pts.

83.0

%

81.6

%

1.4

pts.

Total Health Care

81.9

%

82.0

%

(0.1 )

pts.

81.5

%

81.7

%

(0.2 )

pts.

•
Aetnas third-quarter 2017 Commercial MBR decreased compared with
third-quarter 2016 primarily due to reduced losses in Aetnas
individual Commercial products and improved performance across Aetnas
core Commercial business. The decrease was partially offset by the
unfavorable impact of the temporary suspension of the HIF in 2017.

•
Aetnas third-quarter 2017 Government MBR increased compared with
third-quarter 2016 primarily due to the unfavorable impact of the
temporary suspension of the HIF in 2017.

•
Prior years health care costs payable estimates developed favorably
by $783 million and $717 million during the first nine months of 2017
and 2016, respectively. This development is reported on a basis
consistent with the prior years development reported in the health
care costs payable table in Aetnas annual audited financial
statements, and does not directly correspond to an increase in 2017
operating results.

•
Days claims payable(7) was 54 days at September 30,
2017, consistent with June 30, 2017 and a decrease of three days
compared with September 30, 2016. The year-over-year decrease was
driven by changes in business mix, primarily related to the decline in
Aetnas individual Commercial product membership and the increase in
Aetnas Medicare product membership.

Group Insurance Segment Results

Group Insurance, which includes group life, disability and long-term
care products, reported:

•
Income before income taxes(1) of $53 million for
third-quarter 2017 compared with $27 million for third-quarter 2016.
Pre-tax adjusted earnings(2) were $34 million for
third-quarter 2017 compared with $22 million for third-quarter 2016.
Income before income taxes and pre-tax adjusted earnings increased
primarily due to higher underwriting margins in Aetnas disability
products, partially offset by lower underwriting margins in Aetnas
life products. The increase in income before income taxes also
reflects higher net realized capital gains in third-quarter 2017
compared to third-quarter 2016.

•
Total revenue of $650 million and $621 million for the third quarters
of 2017 and 2016, respectively. Adjusted revenue(3) was
$631 million and $616 million for the third quarters of 2017 and 2016,
respectively. The increase in total revenue and adjusted revenue was
primarily due to higher premiums in Aetnas life and disability
products. The increase in total revenue also reflects higher net
realized capital gains in third-quarter 2017 compared to third-quarter
2016.

•
In October 2017, Aetna entered into a definitive agreement under which
Aetna will sell a substantial portion of its Group Insurance segment
consisting of its domestic group life insurance, group disability
insurance and absence management businesses. The transaction is
expected to close in early November 2017.

Large Case Pensions Segment Results

Large Case Pensions, which manages a variety of discontinued and other
retirement and savings products, primarily for qualified pension plans,
reported:

•
Income before income taxes(1) was $6 million for both the
third quarters of 2017 and 2016. Pre-tax adjusted earnings(2)
were $5 million and $3 million for the third quarters of 2017 and
2016, respectively.

•
Total revenue of $80 million for third-quarter 2017 compared with $70
million for third-quarter 2016. Adjusted revenue(3) was $79
million and $67 million for the third quarters of 2017 and 2016,
respectively. The increase in total revenue and adjusted revenue was
primarily due to higher net investment income.

Aetnas conference call to discuss third-quarter 2017 results will
begin at 8:30 a.m. ET today. The public may access the conference call
through a live audio webcast available on Aetnas Investor Information
website at www.aetna.com/investor.
Financial, statistical and other information, including GAAP
reconciliations, related to the conference call also will be available
on Aetnas Investor Information website.

The conference call also can be accessed by dialing 1-877-709-8150,
or +1-201-689-8354 for international callers. The company suggests
participants dial in approximately 10 minutes before the call. No access
code is required. Individuals who dial in will be asked to identify
themselves and their affiliations.

A replay of the call may be accessed through Aetnas Investor
Information website at www.aetna.com/investor
or by dialing 1-877-660-6853, or +1-201-612-7415 for international
callers. The replay conference ID is 13671637. Telephone replays
will be available until 11 p.m. ET on November 14, 2017.

About Aetna Aetna is one of the nations leading diversified
health care benefits companies, serving an estimated 44.6 million people
with information and resources to help them make better informed
decisions about their health care. Aetna offers a broad range of
traditional, voluntary and consumer-directed health insurance products
and related services, including medical, pharmacy, dental, behavioral
health, group life and disability plans, and medical management
capabilities, Medicaid health care management services, workers
compensation administrative services and health information technology
products and services. Aetnas customers include employer groups,
individuals, college students, part-time and hourly workers, health
plans, health care providers, governmental units, government-sponsored
plans, labor groups and expatriates. For more information, see www.aetna.com
and learn about how Aetna is helping to build a healthier world.
@AetnaNews

Condensed Consolidated Balance Sheets

(Unaudited)

September 30,

December 31,

(Millions)

2017

2016

Assets:

Cash and short-term investments

$

8,797

$

21,042

Accounts receivable, net

4,965

4,580

Other current assets

2,672

2,827

Total current assets

16,434

28,449

Long-term investments

21,507

21,833

Other long-term assets

19,442

18,864

Total assets

$ 57,383

$

69,146

Liabilities and shareholders equity:

Health care costs payable

$

6,139

$

6,558

Current portion of long-term debt

1,998

1,634

Other current liabilities

11,510

10,502

Total current liabilities

19,647

18,694

Long-term debt, less current portion

8,161

19,027

Other long-term liabilities

13,757

13,482

Total Aetna shareholders equity

15,583

17,881

Non-controlling interests

235

62

Total liabilities and equity

$ 57,383

$

69,146

Consolidated Statements of Income

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Millions)

2017

2016

2017

2016

Revenue:

Health care premiums

$

12,710

$

13,525

$ 39,152

$

40,623

Other premiums

562

549

1,658

1,636

Fees and other revenue

1,443

1,454

4,404

4,395

Net investment income

233

219

730

688

Net realized capital gains (losses)

46

34

(262 )

85

Total revenue

14,994

15,781

45,682

47,427

Benefits and expenses:

Health care costs

10,412

11,092

31,905

33,172

Current and future benefits

548

535

1,632

1,589

Operating expenses:

Selling expenses

401

408

1,224

1,245

General and administrative expenses

2,211

2,422

7,793

7,232

Total operating expenses

2,612

2,830

9,017

8,477

Interest expense

90

189

349

414

Amortization of other acquired intangible assets

58

61

176

187

Loss on early extinguishment of long-term debt

--

--

246

--

Reduction of reserve for anticipated future losses on discontinued

--

--

(109 )

(128 )

products

Total benefits and expenses

13,720

14,707

43,216

43,711

Income before income taxes

1,274

1,074

2,466

3,716

Income tax expense

426

477

815

1,588

Net income including non-controlling interests

848

597

1,651

2,128

Less: Net income (loss) attributable to non-controlling interests

10

(7 )

(9 )

(4 )

Net income attributable to Aetna

$

838

$

604

$

1,660

$

2,132

Consolidated Statements of Cash Flows

(Unaudited)

Nine Months Ended

September 30,

(Millions)

2017

2016

Cash flows from operating activities:

Net income including non-controlling interests

$

1,651

$

2,128

Adjustments to reconcile net income to net cash provided by

operating activities:

Net realized capital losses (gains)

262

(85 )

Depreciation and amortization

499

511

Debt fair value amortization

(14 )

(22 )

Equity in (earnings) losses of affiliates, net

(80 )

1

Stock-based compensation expense

135

147

Reduction of reserve for anticipated future losses on discontinued

(109 )

(128 )

products

Amortization of net investment premium

54

62

Loss on early extinguishment of long-term debt

246

--

Changes in assets and liabilities:

Premiums due and other receivables

(184 )

(278 )

Income taxes

(15 )

387

Other assets and other liabilities

(1,196 )

57

Health care and insurance liabilities

931

1,841

Distributions from partnership investments

44

--

Net cash provided by operating activities

2,224

4,621

Cash flows from investing activities:

Proceeds from sales and maturities of investments

8,854

10,747

Cost of investments

(7,860 )

(10,876 )

Additions to property, equipment and software

(301 )

(197 )

Cash used for acquisitions, net of cash acquired

(24 )

--

Net cash provided by (used for) investing activities

669

(326 )

Cash flows from financing activities:

Issuance of long-term debt

988

12,886

Repayment of long-term debt

(11,734 )

--

Common shares issued under benefit plans, net

(132 )

(103 )

Common shares repurchased

(3,845 )

--

Dividends paid to shareholders

(420 )

(262 )

Net payment on interest rate derivatives

--

(274 )

Contributions, non-controlling interests

182

--

Net cash (used for) provided by financing activities

(14,961 )

12,247

Net (decrease) increase in cash and cash equivalents

(12,068 )

16,542

Cash and cash equivalents, beginning of period

17,996

2,524

Cash and cash equivalents, end of period

$

5,928

$

19,066

Reconciliation of the Most Directly Comparable GAAP Measure to

Certain Reported Amounts

Three Months Ended

Three Months Ended

September 30, 2017

September 30, 2016

(Millions, except per common share data)

Total

Per

Total

Per

Reconciliation of net income to adjusted earnings

Company

Common

Company

Common

Share

Share

Net income(1) (GAAP measure)

$

838

$

2.52

$

604

$

1.70

Transaction and integration-related costs

--

--

164

0.46

Amortization of other acquired intangible assets

58

0.17

61

0.17

Net realized capital gains

(46 )

(0.14 )

(34 )

(0.09 )

Income tax benefit

(36 )

(0.10 )

(61 )

(0.17 )

Adjusted earnings(2)

$

814

$

2.45

$

734

$

2.07

Weighted average common shares - diluted

332.0

354.3

Three Months Ended September 30, 2017

Three Months Ended September 30, 2016

(Millions)

Health

Group

Large

Corporate

Total

Health

Group

Large

Corporate

Total

Reconciliation of total revenue to adjusted revenue

Care

Insurance

Case

Financing(8)

Company

Care

Insurance

Case

Financing(8)

Company

Pensions

Pensions

Total revenue (GAAP measure)

$

14,264

$

650

$

80

$ --

$

14,994

$

15,081

$

621

$

70

$

9

$ 15,781

Interest income on proceeds of transaction-related debt

--

--

--

--

--

--

--

--

(9 )

(9 )

Net realized capital gains

(26 )

(19 )

(1 )

--

(46 )

(26 )

(5 )

(3 )

--

(34 )

Adjusted revenue(3) (excludes net realized capital gains

$

14,238

$

631

$

79

$ --

$

14,948

$

15,055

$

616

$

67

$ --

$ 15,738

and an other item)

Reconciliation of income before income taxes to pre-tax adjusted

earnings

Income (loss) before income taxes (GAAP measure)

$

1,279

$

53

$

6

$

(64 )

$

1,274

$

1,270

$

27

$

6

$

(229 )

$

1,074

Less: Income (loss) before income taxes attributable to

14

--

--

--

14

(9 )

--

--

--

(9 )

non-controlling interests (GAAP measure)

Income (loss) before income taxes attributable to Aetna (GAAP

1,265

53

6

(64 )

1,260

1,279

27

6

(229 )

1,083

measure)

Transaction and integration-related costs

--

--

--

--

--

--

--

--

164

164

Amortization of other acquired intangible assets

58

--

--

--

58

61

--

--

--

61

Net realized capital gains

(26 )

(19 )

(1 )

--

(46 )

(26 )

(5 )

(3 )

--

(34 )

Pre-tax adjusted earnings (loss)(2)

$

1,297

$

34

$

5

$

(64 )

$

1,272

$

1,314

$

22

$

3

$

(65 )

$

1,274

Reconciliation of the Most Directly Comparable GAAP Measure to

Certain Reported Amounts

Nine Months Ended

Nine Months Ended

September 30, 2017

September 30, 2016

(Millions, except per common share data)

Total

Per

Total

Per

Reconciliation of net income to adjusted earnings

Company

Common

Company

Common

Share

Share

Net income(1) (GAAP measure)

$

1,660

$

4.92

$

2,132

$

6.02

Loss on early extinguishment of long-term debt

246

0.73

--

--

Penn Treaty-related guaranty fund assessments

231

0.68

--

--

Transaction and integration-related costs

1,202

3.56

333

0.94

Reduction of reserve for anticipated future losses on discontinued

(109 )

(0.32 )

(128 )

(0.36 )

products

Amortization of other acquired intangible assets

176

0.52

187

0.53

Net realized capital losses (gains)

262

0.78

(85 )

(0.24 )

Income tax benefit

(770 )

(2.28 )

(100 )

(0.28 )

Adjusted earnings(2)

$

2,898

$

8.59

$

2,339

$

6.61

Weighted average common shares - diluted

337.5

354.1

Nine Months Ended September 30, 2017

Nine Months Ended September 30, 2016

(Millions)

Health

Group

Large

Corporate

Total

Health

Group

Large

Corporate

Total

Reconciliation of total revenue to adjusted revenue

Care

Insurance

Case

Financing(8)

Company

Care

Insurance

Case

Financing(8)

Company

Pensions

Pensions

Total revenue (GAAP measure)

$

43,847

$

1,913

$

247

$

(325 )

$ 45,682

$

45,316

$

1,880

$

219

$

12

$

47,427

Interest income on proceeds of transaction-related debt

--

--

--

(11 )

(11 )

--

--

--

(12 )

(12 )

Net realized capital (gains) losses

(34 )

(36 )

(4 )

336

262

(51 )

(25 )

(9 )

--

(85 )

Adjusted revenue(3) (excludes net realized capital

$

43,813

$

1,877

$

243

$ --

$ 45,933

$

45,265

$

1,855

$

210

$ --

$

47,330

(gains) losses and an other item)

Reconciliation of income before income taxes to pre-tax adjusted

earnings

Income (loss) before income taxes (GAAP measure)

$

4,165

$

145

$

126

$

(1,970 )

$

2,466

$

3,971

$

129

$

143

$

(527 )

$

3,716

Less: (Loss) income before income taxes attributable to

(7 )

--

1

--

(6 )

(4 )

--

(1 )

--

(5 )

non-controlling interests (GAAP measure)

Income (loss) before income taxes attributable to Aetna (GAAP

4,172

145

125

(1,970 )

2,472

3,975

129

144

(527 )

3,721

measure)

Loss on early extinguishment of long-term debt

--

--

--

246

246

--

--

--

--

--

Penn Treaty-related guaranty fund assessments

231

--

--

--

231

--

--

--

--

--

Transaction and integration-related costs

--

--

--

1,202

1,202

--

--

--

333

333

Reduction of reserve for anticipated future losses on discontinued

--

--

(109 )

--

(109 )

--

--

(128 )

--

(128 )

products

Amortization of other acquired intangible assets

176

--

--

--

176

187

--

--

--

187

Net realized capital (gains) losses

(34 )

(36 )

(4 )

336

262

(51 )

(25 )

(9 )

--

(85 )

Pre-tax adjusted earnings (loss)(2)

$

4,545

$

109

$

12

$

(186 )

$

4,480

$

4,111

$

104

$

7

$

(194 )

$

4,028

Margins and Ratios

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Millions)

2017

2016

2017

2016

Reconciliation of income before income taxes to adjusted earnings

before income taxes, excluding interest expense:

Income before income taxes (GAAP measure)

$

1,274

$

1,074

$

2,466

$

3,716

Interest expense(9)

90

80

264

237

Loss on early extinguishment of long-term debt

--

--

246

--

Penn Treaty-related guaranty fund assessments

--

--

231

--

Transaction and integration-related costs

--

164

1,202

333

Reduction of reserve for anticipated future losses on discontinued

--

--

(109 )

(128 )

products

Amortization of other acquired intangible assets

58

61

176

187

Net realized capital (gains) losses

(46 )

(34 )

262

(85 )

Adjusted earnings(2) before income taxes, excluding

(A)

$

1,376

$

1,345

$

4,738

$

4,260

interest expense

Reconciliation of net income to adjusted earnings excluding

interest expense, net of tax:

Net income(1) (GAAP measure)

(B)

$

838

$

604

$

1,660

$

2,132

Interest expense(9)

90

80

264

237

Loss on early extinguishment of long-term debt

--

--

246

--

Penn Treaty-related guaranty fund assessments

--

--

231

--

Transaction and integration-related costs

--

164

1,202

333

Reduction of reserve for anticipated future losses on discontinued

--

--

(109 )

(128 )

products

Amortization of other acquired intangible assets

58

61

176

187

Net realized capital (gains) losses

(46 )

(34 )

262

(85 )

Income tax benefit

(68 )

(89 )

(863 )

(183 )

Adjusted earnings(2) excluding interest expense, net of

$

872

$

786

$

3,069

$

2,493

tax

Reconciliation of total revenue to adjusted revenue:

Total revenue (GAAP measure)

(C)

$

14,994

$

15,781

$ 45,682

$

47,427

Interest income on proceeds of transaction-related debt

--

(9 )

(11 )

(12 )

Net realized capital (gains) losses

(46 )

(34 )

262

(85 )

Adjusted revenue(3) (excludes net realized capital

(D)

$

14,948

$

15,738

$ 45,933

$

47,330

(gains) losses and an other item)

Reconciliation of total operating expenses to adjusted operating

expenses:

Total operating expenses (GAAP measure)

(E)

$

2,612

$

2,830

$

9,017

$

8,477

Penn Treaty-related guaranty fund assessments

--

--

(231 )

--

Transaction and integration-related costs

--

(64 )

(1,128 )

(168 )

Adjusted operating expenses

(F)

$

2,612

$

2,766

$

7,658

$

8,309

Net income and adjusted pre-tax margins:

After-tax net income margin (GAAP measure)

(B)/(C)

5.6

%

3.8

%

3.6

%

4.5

%

Adjusted pre-tax margin(6)

(A)/(D)

9.2

%

8.5

%

10.3

%

9.0

%

Expense ratios:

Total company expense ratio (GAAP measure)

(E)/(C)

17.4

%

17.9

%

19.7

%

17.9

%

Adjusted expense ratio(5)

(F)/(D)

17.5

%

17.6

%

16.7

%

17.6

%

Health Care, Group Insurance and Corporate Financing Operating

Cash Flow as a Percentage of Net Income

Nine Months Ended

September 30,

(Millions)

2017

2016

Net cash provided by operating activities (GAAP measure)

$ 2,224

$

4,621

Less: Net cash used for operating activities: Large Case Pensions

(196 )

(186 )

Net cash provided by operating activities: Health Care, Group

(A)

2,420

4,807

Insurance and Corporate Financing

Net income(1) (GAAP Measure)

1,660

2,132

Less: Net income: Large Case Pensions

88

99

Net income: Health Care, Group Insurance and Corporate Financing

(B)

$ 1,572

$

2,033

Operating cash flow as a percentage of net income:

Operating cash flow as a percentage of net income(1)

(A)/(B)

153.9

%

236.4

%

(GAAP Measure)

Footnotes

(1) Net income refers to net income attributable to Aetna
reported in Aetnas Consolidated Statements of Income in accordance with
U.S. generally accepted accounting principles ("GAAP"). Income before
income taxes refers to income before income taxes attributable to Aetna
in accordance with GAAP. Unless otherwise indicated, all references in
this press release to net income, net income per share and income before
income taxes exclude amounts attributable to non-controlling interests.

•
Other items, if any, that neither relate to the ordinary course of
Aetnas business nor reflect Aetnas underlying business performance.

Although the excluded items may recur, management believes the non-GAAP
financial measures Aetna discloses, including those described above,
provide a more useful comparison of Aetnas underlying business
performance from period to period. Prior to March 31, 2017, operating
earnings was the measure reported to the chief executive officer for
purposes of assessing financial performance and making operating
decisions, such as the allocation of resources among Aetnas business
segments. Effective March 31, 2017, the chief executive officer assesses
consolidated Aetna results based on adjusted earnings and assesses
business segment results based on pre-tax adjusted earnings because
income taxes are recorded in Aetnas Corporate Financing segment and are
not allocated to Aetnas business segments. Also effective March 31,
2017, transaction and integration-related costs were reclassified to
Aetnas Corporate Financing segment because they do not reflect Aetnas
underlying business performance. The prior periods have been restated to
reflect this presentation. Non-GAAP financial measures Aetna discloses,
including those described above, should not be considered a substitute
for, or superior to, financial measures determined or calculated in
accordance with GAAP.

For the periods covered in this press release, the following items are
excluded from the non-GAAP financial measures described above, as
applicable, because Aetna believes they neither relate to the ordinary
course of Aetnas business nor reflect Aetnas underlying business
performance:

•
During the nine months ended September 30, 2017, Aetna incurred losses
on the early extinguishment of long-term debt due to (a) the mandatory
redemption of $10.2 billion aggregate principal amount of certain of
its senior notes issued in June 2016 (collectively, the "SMR Notes")
following the termination of the definitive agreement (the "Humana
Merger Agreement") to acquire Humana Inc. ("Humana") and (b) the early
redemption of $750 million aggregate principal amount of its
outstanding senior notes due 2020.

•
During the nine months ended September 30, 2017, Aetna recorded an
expense for estimated future guaranty fund assessments related to Penn
Treaty Network America Insurance Company and one of its subsidiaries
(collectively, "Penn Treaty"), which was placed in rehabilitation in
2009 and placed in liquidation in March 2017. This expense does not
directly relate to the underwriting or servicing of products for
customers and is not directly related to the core performance of
Aetnas business operations.

•
Aetna recorded transaction and integration-related costs during the
nine months ended September 30, 2017 and the three and nine months
ended September 30, 2016 primarily related to its proposed acquisition
of Humana (the "Humana Transaction"). Transaction costs include costs
associated with the termination of the Humana Merger Agreement, the
termination of Aetnas agreement to sell certain assets to Molina
Healthcare, Inc. and advisory, legal and other professional fees which
are reflected in Aetnas GAAP Consolidated Statements of Income in
general and administrative expenses. Transaction costs also include
the negative cost of carry associated with the debt financing that
Aetna obtained in June 2016 for the Humana Transaction. Prior to the
mandatory redemption of the SMR Notes, the negative cost of carry
associated with these senior notes was excluded from adjusted earnings
and pre-tax adjusted earnings. The negative cost of carry associated
with the $2.8 billion aggregate principal amount of Aetnas senior
notes issued in June 2016 that are not subject to mandatory redemption
(the "Other 2016 Senior Notes") was excluded from adjusted earnings
and pre-tax adjusted earnings through the date of the termination of
the Humana Merger Agreement. The components of the negative cost of
carry are reflected in Aetnas GAAP Consolidated Statements of Income
in interest expense and net investment income. Subsequent to the
termination of the Humana Merger Agreement, the interest expense and
net investment income associated with the Other 2016 Senior Notes were
no longer excluded from adjusted earnings and pre-tax adjusted
earnings.

•
In 1993, Aetna discontinued the sale of fully guaranteed large case
pensions products and established a reserve for anticipated future
losses on these products, which Aetna reviews quarterly. During both
the nine months ended September 30, 2017 and 2016, Aetna reduced the
reserve for anticipated future losses on discontinued products. Aetna
believes excluding any changes in the reserve for anticipated future
losses on discontinued products from adjusted earnings provides more
useful information as to Aetnas continuing products and is consistent
with the treatment of the operating results of these discontinued
products, which are credited or charged to the reserve and do not
affect Aetnas operating results.

•
Other acquired intangible assets relate to Aetnas acquisition
activities and are amortized over their useful lives. However, this
amortization does not directly relate to the underwriting or servicing
of products for customers and is not directly related to the core
performance of Aetnas business operations.

•
Net realized capital gains and losses arise from various types of
transactions, primarily in the course of managing a portfolio of
assets that support the payment of liabilities. However, these
transactions do not directly relate to the underwriting or servicing
of products for customers and are not directly related to the core
performance of Aetnas business operations.

•
The corresponding tax benefit or expense related to the items excluded
from adjusted earnings discussed above. The tax benefit or expense was
calculated utilizing the appropriate tax rate for each individual item
excluded from adjusted earnings. The three months ended September 30,
2017 include a $29 million tax benefit which reflects anticipated
incremental tax benefits related to certain costs associated with the
Humana Transaction.

For a reconciliation of financial measures calculated under GAAP to
these items, refer to the tables on pages 9 through 11 of this press
release.

(3) Adjusted revenue excludes net realized capital gains and
losses and interest income on the proceeds of Aetnas senior notes
issued in June 2016 as noted in (2) above. Refer to the
tables on pages 9 through 11 of this press release for a reconciliation
of total revenue calculated under GAAP to adjusted revenue.

(4) Projected full-year 2017 net income per share and
adjusted earnings per share reflect a range of 334 million to 335
million weighted average diluted shares. Projected full-year 2017
adjusted earnings per share exclude from projected full-year 2017 net
income per share the loss on early extinguishment of long-term debt, the
projected Penn Treaty-related guaranty fund assessments, projected
transaction and integration-related costs (including termination costs)
primarily related to the Humana Transaction, the reduction of the
reserve for anticipated future losses on discontinued products,
estimated amortization of other acquired intangible assets, net realized
capital gains and losses, other items, if any, that neither relate to
the ordinary course of Aetnas business nor reflect Aetnas underlying
business performance and the corresponding income tax benefit or expense
related to the items excluded from net income per share discussed above.
Amortization of other acquired intangible assets relates to Aetnas
acquisition activities. The table below reconciles projected 2017 net
income per share to projected 2017 adjusted earnings per share:

Reconciliation of Projected 2017 Net Income Per Share to

Projected 2017 Adjusted Earnings Per Share

Projected net income per share (GAAP measure)

Approximately

$

5.95

Loss on early extinguishment of long-term debt

.74

Penn Treaty-related guaranty fund assessments

.69

Transaction and integration-related costs (including termination

3.59

costs)

Reduction of reserve for anticipated future losses on discontinued

(.33 )

products

Amortization of other acquired intangible assets

.70

Net realized capital losses

.78

Income tax benefit

(2.37 )

Projected adjusted earnings per share

Approximately

$

9.75

Aetna will experience net realized capital gains or net realized capital
losses during the remainder of 2017, however Aetna cannot project the
amount of such future gains or losses. Therefore, Aetna has assumed no
net realized capital gains or losses after September 30, 2017 for
purposes of projecting net income and net income per share. Aetnas
annual net realized capital gains or losses ranged from a net realized
capital loss of $65 million to a net realized capital gain of $86
million during calendar years 2014 through 2016.

(5) The adjusted expense ratio excludes net realized capital
gains and losses and other items, if any, that are excluded from
adjusted revenue or adjusted operating expenses, as noted in (2)
above. For a reconciliation of the comparable GAAP measure to this
metric for the periods covered by this press release, refer to page 11
of this press release.

(6) In order to provide useful information regarding Aetnas
profitability on a basis comparable to others in the industry, without
regard to financing decisions, income taxes or amortization of other
acquired intangible assets (each of which may vary for reasons not
directly related to the performance of the underlying business), Aetnas
adjusted pre-tax margin is based on adjusted earnings excluding interest
expense and income taxes. Management also uses adjusted pre-tax margin
to assess Aetnas performance, including performance versus competitors.

(7) Days claims payable is calculated by dividing the health
care costs payable at each quarter end by the average health care costs
per day in each respective quarter. The total debt to consolidated
capitalization ratio is calculated by dividing total long-term debt and
short-term debt ("Total Debt") by the sum of Total Debt and total Aetna
shareholders equity.

(8) Aetnas Corporate Financing segment is not a business
segment. It is added to Aetnas business segments to reconcile segment
reporting to Aetnas consolidated results. The Corporate Financing
segment includes interest expense on Aetnas outstanding debt and the
financing components of Aetnas pension and other postretirement
employee benefit plan expenses (benefits), and, effective March 31,
2017, all transaction and integration-related costs and income taxes.
The prior periods have been restated to reflect this presentation. As
described in (2) above, the adjusted earnings of the
Corporate Financing segment exclude other items, if any, that neither
relate to the ordinary course of Aetnas business nor reflect Aetnas
underlying business performance.

(9) Interest expense included in the reconciliation to
adjusted earnings before income taxes, excluding interest expense and
the reconciliation to adjusted earnings excluding interest expense, net
of tax for the nine months ended September 30, 2017 and the three and
nine months ended September 30, 2016 excludes costs associated with the
term loan credit agreement executed in connection with the Humana
Transaction and the negative cost of carry on transaction-related debt
incurred in connection with the Humana Transaction. Interest expense for
the nine months ended September 30, 2016 excludes costs associated with
bridge credit agreement executed in connection with the Humana
Transaction. These costs are included within transaction and
integration-related costs. Refer to (2) above for further
discussion.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You can
generally identify forward-looking statements by the use of
forward-looking terminology such as "anticipate," "believe," "can,"
"continue," "could," "estimate," "evaluate," "expect," "explore,"
"forecast," "guidance," "intend," "likely," "may," "might," "outlook,"
"plan," "potential," "predict," "probable," "project," "seek," "should,"
"view," or "will," or the negative thereof or other variations thereon
or comparable terminology. These forward-looking statements are only
predictions and involve known and unknown risks and uncertainties, many
of which are beyond Aetnas control.

Statements in this press release regarding Aetna that are
forward-looking, including Aetnas projections as to net income per
share, adjusted earnings per share, Penn Treaty-related guaranty fund
assessments, transaction and integration-related costs, amortization of
other acquired intangible assets, the income tax benefit related to
items excluded from adjusted earnings, weighted average diluted shares,
and future operating results, are based on managements estimates,
assumptions and projections, and are subject to significant
uncertainties and other factors, many of which are beyond Aetnas
control. Important risk factors could cause actual future results and
other future events to differ materially from those currently estimated
by management, including, but not limited to: unanticipated increases in
medical costs (including increased intensity or medical utilization as a
result of flu or otherwise; changes in membership mix to higher cost or
lower-premium products or membership adverse selection; medical cost
increases resulting from unfavorable changes in contracting or
re-contracting with providers (including as a result of provider
consolidation and/or integration); increased pharmacy costs (including
in Aetnas public health insurance exchange products)); the
profitability of Aetnas individual products, where membership is higher
than Aetna previously projected and has had and may continue to have
more adverse health status and/or higher medical benefit utilization
(including due to Aetnas product exit strategy) than Aetna projected;
any suspension of the ACAs health insurer fee for 2018; adverse impacts
from any failure to raise the U.S. Federal governments debt ceiling or
any sustained U.S. Federal government shut down; and changes in Aetnas
future cash requirements, capital requirements, results of operations,
financial condition and/or cash flows. As currently enacted, health care
reform will continue to significantly impact Aetnas business operations
and financial results, including Aetnas pricing and medical benefit
ratios, and key components of the legislation will continue to be phased
in through 2020. Aetna will be required to dedicate material resources
and incur material expenses during 2017 to implement health care reform.
Significant parts of the legislation continue to evolve through the
promulgation of regulations and guidance. In addition, pending efforts
in the U.S. Congress to repeal, amend, replace or restrict funding for
various aspects of health care reform and pending litigation challenging
aspects of the law and its implementation continue to create additional
uncertainty about the ultimate impact of health care reform. As a
result, many of the impacts of health care reform are unknown. Other
important risk factors include: adverse changes in federal or state
government policies, legislation or regulations (including legislative,
judicial or regulatory measures that would affect Aetnas business
model, repeal, restrict funding for or amend various aspects of health
care reform, limit Aetnas ability to price for the risk it assumes
and/or reflect reasonable costs or profits in its pricing, such as
mandated minimum medical benefit ratios, or eliminate or reduce ERISA
pre-emption of state laws (increasing Aetnas potential litigation
exposure)); uncertainty related to Aetnas accruals for the ACAs
reinsurance, risk adjustment and risk corridor programs ("3Rs");
uncertainty related to the funding for and final reconciliations with
respect to the ACAs risk management and subsidy programs; the
implementation of health care reform legislation, collection of ACA
fees, assessments and taxes through increased premiums; adverse
legislative, regulatory and/or judicial changes to or interpretations of
existing health care reform legislation and/or regulations (including
those relating to minimum medical loss ratio ("MLR") rebates); the
timing and amount of and payment methods for satisfying assessments for
Penn Treaty Network America Insurance Company and other insolvent payors
under state guaranty fund laws; adverse and less predictable economic
conditions in the U.S. and abroad (including unanticipated levels of, or
increases in the rate of, unemployment); reputational or financial
issues arising from Aetnas social media activities, data security
breaches, other cybersecurity risks or other causes; adverse program,
pricing, funding or audit actions by federal or state government payors,
including as a result of sequestration and/or changes to or curtailment
or elimination of the Centers for Medicare & Medicaid Services ("CMS")
star rating bonus payments; Aetnas ability to maintain and/or enhance
its CMS star ratings; Aetnas ability to diversify Aetnas sources of
revenue and earnings (including by developing and expanding Aetnas
consumer business and expanding Aetnas foreign operations), transform
Aetnas business model, develop new products and optimize Aetnas
business platforms; the success of Aetnas consumer health and services
initiatives; adverse changes in size, product or geographic mix or
medical cost experience of membership; managing executive succession and
key talent retention, recruitment and development; failure to achieve
and/or delays in achieving desired rate increases and/or profitable
membership growth due to regulatory review or other regulatory
restrictions, an uncertain economy and/or significant competition,
especially in key geographic areas where membership is concentrated,
including successful protests of business awarded to Aetna; failure to
adequately implement health care reform and/or repeal of or changes in
health care reform; the outcome of various litigation and regulatory
matters, including audits, challenges to Aetnas minimum MLR rebate
methodology and/or reports, intellectual property litigation and
litigation concerning, and ongoing reviews by various regulatory
authorities of, certain of Aetnas payment practices with respect to
out-of-network providers, other providers and/or life insurance
policies; Aetnas ability to integrate, simplify, and enhance Aetnas
existing products, processes and information technology systems and
platforms to keep pace with changing customer and regulatory needs;
Aetnas ability to successfully integrate Aetnas businesses (including
businesses Aetna may acquire in the future), separate divested
businesses and implement multiple strategic and operational initiatives
simultaneously; Aetnas ability to manage health care and other benefit
costs; Aetnas ability to reduce administrative expenses while
maintaining targeted levels of service and operating performance;
failure by a service provider to meet its obligations to Aetna; Aetnas
ability to develop and maintain relationships (including joint ventures
or other collaborative risk-sharing agreements) with providers while
taking actions to reduce medical costs and/or expand the services Aetna
offers; Aetnas ability to demonstrate that Aetnas products and
processes lead to access to quality affordable care by Aetnas members;
Aetnas ability to maintain its relationships with third-party brokers,
consultants and agents who sell its products; collection of amounts
payable to Aetna by the State of Illinois; increases in medical costs or
Group Insurance claims resulting from any epidemics, acts of terrorism
or other extreme events; changes in medical cost estimates due to the
necessary extensive judgment that is used in the medical cost estimation
process, the considerable variability inherent in such estimates, the
implementation of public health insurance exchanges; and the sensitivity
of such estimates to changes in medical claims payment patterns and
changes in medical cost trends; and a downgrade in Aetnas financial
ratings. For more discussion of important risk factors that may
materially affect Aetna, please see the risk factors contained in
Aetnas 2016 Annual Report on Form 10-K ("Aetnas 2016 Annual Report")
and Aetnas Quarterly Report on Form 10-Q for the quarter ended June 30,
2017 ("Aetnas June 2017 Quarterly Report"), each on file with the
Securities and Exchange Commission ("SEC"), and Aetnas Quarterly Report
on Form 10-Q for the quarter ended September 30, 2017 ("Aetnas
September 2017 Quarterly Report"), when filed with the SEC. You should
also read Aetnas 2016 Annual Report and Aetnas June 2017 Quarterly
Report, each on file with the SEC, and Aetnas September 2017 Quarterly
Report, when filed with the SEC for a discussion of Aetnas historical
results of operations and financial condition.

No assurances can be given that any of the events anticipated by the
forward-looking statements will transpire or occur, or if any of them do
occur, what impact they will have on the results of operations,
financial condition or cash flows of Aetna. Aetna does not assume any
duty to update or revise forward-looking statements, whether as a result
of new information, future events or otherwise, as of any future date.

Supplementary Information

Statements of Income Before Income Taxes Attributable to Aetna by

Segment (Unaudited)

Health

Group

Large Case

Corporate

(Millions)

Care

Insurance

Pensions

Financing

Total

Three Months Ended September 30, 2017

Revenue:

Health care premiums

$

12,710

$ --

$ --

$ --

$ 12,710

Other premiums

--

552

10

--

562

Fees and other revenue

1,417

24

2

--

1,443

Net investment income

111

55

67

--

233

Net realized capital gains

26

19

1

--

46

Total revenue

14,264

650

80

--

14,994

Benefits and expenses:

Health care costs

10,412

--

--

--

10,412

Current and future benefits

--

478

70

--

548

Operating expenses:

Selling expenses

366

35

--

--

401

General and administrative expenses

2,149

84

4

(26 )

2,211

Total operating expenses

2,515

119

4

(26 )

2,612

Interest expense

--

--

--

90

90

Amortization of other acquired intangible assets

58

--

--

--

58

Total benefits and expenses

12,985

597

74

64

13,720

Income (loss) before income taxes including non-controlling interests

1,279

53

6

(64 )

1,274

Less: Income before income taxes attributable to non-controlling

14

--

--

--

14

interests

Income (loss) before income taxes attributable to Aetna

$

1,265

$

53

$

6

$

(64 )

$

1,260

Three Months Ended September 30, 2016

Revenue:

Health care premiums

$

13,525

$ --

$ --

$ --

$ 13,525

Other premiums

--

537

12

--

549

Fees and other revenue

1,425

27

2

--

1,454

Net investment income

105

52

53

9

219

Net realized capital gains

26

5

3

--

34

Total revenue

15,081

621

70

9

15,781

Benefits and expenses:

Health care costs

11,092

--

--

--

11,092

Current and future benefits

--

474

61

--

535

Operating expenses:

Selling expenses

377

31

--

--

408

General and administrative expenses

2,281

89

3

49

2,422

Total operating expenses

2,658

120

3

49

2,830

Interest expense

--

--

--

189

189

Amortization of other acquired intangible assets

61

--

--

--

61

Total benefits and expenses

13,811

594

64

238

14,707

Income (loss) before income taxes including non-controlling interests

1,270

27

6

(229 )

1,074

Less: Loss before income taxes attributable to non-controlling

(9 )

--

--

--

(9 )

interests

Income (loss) before income taxes attributable to Aetna

$

1,279

$

27

$

6

$

(229 )

$

1,083

Statements of Income Before Income Taxes Attributable to Aetna by

Segment (Unaudited)

Health

Group

Large Case

Corporate

(Millions)

Care

Insurance

Pensions

Financing

Total

Nine Months Ended September 30, 2017

Revenue:

Health care premiums

$

39,152

$ --

$ --

$ --

$ 39,152

Other premiums

--

1,622

36

--

1,658

Fees and other revenue

4,322

76

6

--

4,404

Net investment income

339

179

201

11

730

Net realized capital gains (losses)

34

36

4

(336 )

(262 )

Total revenue

43,847

1,913

247

(325 )

45,682

Benefits and expenses:

Health care costs

31,905

--

--

--

31,905

Current and future benefits

--

1,411

221

--

1,632

Operating expenses:

Selling expenses

1,116

108

--

--

1,224

General and administrative expenses

6,485

249

9

1,050

7,793

Total operating expenses

7,601

357

9

1,050

9,017

Interest expense

--

--

--

349

349

Amortization of other acquired intangible assets

176

--

--

--

176

Loss on early extinguishment of long-term debt

--

--

--

246

246

Reduction of reserve for anticipated future losses on discontinued

--

--

(109 )

--

(109 )

products

Total benefits and expenses

39,682

1,768

121

1,645

43,216

Income (loss) before income taxes including non-controlling interests

4,165

145

126

(1,970 )

2,466

Less: (Loss) income before income taxes attributable to

(7 )

--

1

--

(6 )

non-controlling interests

Income (loss) before income taxes attributable to Aetna

$

4,172

$

145

$

125

$

(1,970 )

$

2,472

Nine Months Ended September 30, 2016

Revenue:

Health care premiums

$

40,623

$ --

$ --

$ --

$ 40,623

Other premiums

--

1,604

32

--

1,636

Fees and other revenue

4,309

79

7

--

4,395

Net investment income

333

172

171

12

688

Net realized capital gains

51

25

9

--

85

Total revenue

45,316

1,880

219

12

47,427

Benefits and expenses:

Health care costs

33,172

--

--

--

33,172

Current and future benefits

--

1,394

195

--

1,589

Operating expenses:

Selling expenses

1,150

95

--

--

1,245

General and administrative expenses

6,836

262

9

125

7,232

Total operating expenses

7,986

357

9

125

8,477

Interest expense

--

--

--

414

414

Amortization of other acquired intangible assets

187

--

--

--

187

Reduction of reserve for anticipated future losses on discontinued

--

--

(128 )

--

(128 )

products

Total benefits and expenses

41,345

1,751

76

539

43,711

Income (loss) before income taxes including non-controlling interests

3,971

129

143

(527 )

3,716

Less: Loss before income taxes attributable to non-controlling

(4 )

--

(1 )

--

(5 )

interests

Income (loss) before income taxes attributable to Aetna

$

3,975

$

129

$

144

$

(527 )

$

3,721

Membership

September 30, 2017

June 30, 2017

December 31, 2016

September 30, 2016

(Thousands)

Insured

ASC

Total

Insured

ASC

Total

Insured

ASC

Total

Insured

ASC

Total

Medical Membership:

Commercial

4,584

13,470

18,054

4,407

13,375

17,782

5,457

13,132

18,589

5,596

13,064

18,660

Medicare Advantage

1,467

--

1,467

1,453

--

1,453

1,362

--

1,362

1,364

--

1,364

Medicare Supplement

733

--

733

724

--

724

685

--

685

667

--

667

Medicaid

1,311

600

1,911

1,307

822

2,129

1,668

806

2,474

1,629

801

2,430

Total Medical Membership

8,095

14,070

22,165

7,891

14,197

22,088

9,172

13,938

23,110

9,256

13,865

23,121

Dental Membership:

Total Dental Membership

5,538

7,930

13,468

5,534

8,078

13,612

6,086

8,386

14,472

5,940

8,393

14,333

Pharmacy Benefit Management Services Membership:

Commercial

7,994

8,087

9,400

9,610

Medicare Prescription Drug Plan (stand-alone)

2,074

2,062

2,067

2,031

Medicare Advantage Prescription Drug Plan

1,124

1,116

953

952

Medicaid

2,493

2,832

2,783

2,719

Total Pharmacy Benefit Management Services Membership

13,685

14,097

15,203

15,312

Health Care Medical Benefit Ratios

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Millions)

2017

2016

2017

2016

Premiums (GAAP measure)

Commercial

$

6,043

$

6,952

$ 18,419

$ 20,967

Government

6,667

6,573

20,733

19,656

Health Care

$ 12,710

$ 13,525

$ 39,152

$ 40,623

Health Care Costs (GAAP measure)

Commercial

$

4,917

$

5,829

$ 14,688

$ 17,128

Government

5,495

5,263

17,217

16,044

Health Care

$ 10,412

$ 11,092

$ 31,905

$ 33,172

Medical Benefit Ratios "MBRs"

Commercial

81.4

%

83.8

%

79.7

%

81.7

%

Government

82.4

%

80.1

%

83.0

%

81.6

%

Health Care

81.9

%

82.0

%

81.5

%

81.7

%

Roll Forward of Health Care Costs Payable

(Unaudited)

Nine Months Ended

September 30,

(Millions)

2017

2016

Health care costs payable, beginning of period

$ 6,558

$

6,306

Less: reinsurance recoverables

5

4

Health care costs payable, beginning of period, net

6,553

6,302

Add: Components of incurred health care costs:

Current year

32,611

33,804

Prior years(a)

(783 )

(717 )

Total incurred health care costs (b)

31,828

33,087

Less: Claims paid

Current year

26,959

27,382

Prior years

5,364

5,222

Total claims paid

32,323

32,604

Health care costs payable, end of period, net

6,058

6,785

Add: premium deficiency reserve

77

85

Add: reinsurance recoverables

4

3

Health care costs payable, end of period

$ 6,139

$

6,873

(a) Negative amounts reported for incurred health care costs
related to prior years result from claims being settled for amounts less
than originally estimated. (b) Total incurred health
care costs exclude from the table above $77 million and $85 million,
respectively, related to the premium deficiency reserve recorded during
the nine months ended September 30, 2017 and 2016, for the 2017 and 2016
coverage years primarily related to Aetnas individual Commercial
products.

Days Claims Payable (Unaudited)

September 30, 2017

June 30, 2017

March 31, 2017

December 31, 2016

September 30, 2016

Days Claims Payable

54

54

53

54

57

Health Care Reforms Reinsurance, Risk Adjustment and Risk

Corridor (the "3Rs")(a) Net Receivable (Payable)

September 30, 2017

December 31, 2016

(Unaudited)

(Millions)

Reinsurance

Risk Adjustment

Risk Corridor(b)

Reinsurance

Risk Adjustment

Risk Corridor

Current

$

37

$

(42 )

$

(6 )

$

202

$

(690 )

$

(10 )

Long-term

--

28

--

--

--

--

Total net receivable (payable)

$

37

$

(14 )

$

(6 )

$

202

$

(690 )

$

(10 )

(a) Aetna participates in certain public health insurance
exchanges established pursuant to the Patient Protection and Affordable
Care Act and the Health Care and Education Reconciliation Act of 2010
(as amended, collectively, "Health Care Reform" or the "ACA"). Under
regulations established by the U.S. Department of Health and Human
Services ("HHS"), HHS pays Aetna a portion of the premium and through
September 30, 2017, paid a portion of the health care costs for
low-income individual Public Exchange members. In addition, HHS
administers the 3Rs risk management programs. The ACAs temporary
Reinsurance and Risk Corridor programs expired at the end of 2016. (b)
Aetna estimates that as of September 30, 2017, it is entitled to
receive a total of $314 million from HHS under the three-year ACA risk
corridor program for the 2014 through 2016 program years. At
September 30, 2017, Aetna did not record any ACA risk corridor
receivables related to the 2016 or 2015 program years or any amount in
excess of HHSs announced prorated funding amount for the 2014 program
year, because payments from HHS are uncertain.